ClinicalTrials.gg
CompletedNCT06272981PulseSmartUpdated Nov 17, 2026Results posted

A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS

An interventional study of Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation in Atrial Fibrillation, sponsored by Biosense Webster, Inc.. Completed at 7 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Biosense Webster, Inc. (part of Johnson & Johnson) · Not applicable, Interventional, and Treatment

How we know

Updated Nov 17, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
136
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Atrial Fibrillation by Johnson & Johnson — 7 open to participants now, 12 under way, 1 of them phase 3. Atrial Fibrillation · Johnson & Johnson.

Enrollment
33rd of 58
136 · median 149
Started
2024
with 2 others
No phase
34 of 71
6 open now
Registered
60th of 71
by date

Among the 71 studies in Atrial Fibrillation by Johnson & Johnson, this one is the 33rd largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2024, is one of 34 with no phase, and was the 60th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

7 of the 71 studies in Atrial Fibrillation by Johnson & Johnson are open now, in 5 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Atrial Fibrillation by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate safety and effectiveness of the Biosense Webster (BWI) ablation system (THERMOCOOL SMARTTOUCH surround flow [STSF] catheter and TRUPULSE generator) when used for isolation of the atrial pulmonary veins (PVs) in treatment of participants with paroxysmal atrial fibrillation (PAF), an irregular heart rate that causing abnormal blood flow.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria::

  • Diagnosed with Symptomatic PAF (Physician's note indicating recurrent self-terminating AF). At least one (1) electrocardiographically documented AF episode within twelve (12) months prior to enrollment. Electrocardiographic documentation may include, but is not limited to, (ECG), Holter monitor, or other electrocardiographical devices accepted by investigators
  • Failed at least one (1) Class I or Class III Antiarrhythmic Drug (AAD) as evidenced by recurrent symptomatic AF or has intolerable side effects or is to the Class I or Class III AAD
  • Able and willing to comply with all pre-procedure, post-procedure, and follow-up testing and visit requirements
  • Willing and capable of providing consent

Exclusion Criteria:

  • AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause (e.g., untreated documented obstructive sleep apnea and acute alcohol toxicity)
  • Previous LA ablation or surgery
  • Patients known to require ablation outside the PV region (atrioventricular reentrant tachycardia, atrioventricular nodal reentry tachycardia, atrial tachycardia, atrial flutter of unknown origin, ventricular tachycardia and Wolff-Parkinson-White)
  • Previously diagnosed with persistent AF (> 7 days in duration)
  • Severe dilatation of the LA (documented LAD >50mm antero-posterior diameter on imaging within 6 months prior to enrollment
  • Documented left atrium (LA) thrombus within 48 hours prior to the index procedure by Transesophageal Echocardiography (TEE), or by Intracardiac Echocardiography (ICE) prior to transeptal puncture during procedure
  • Documented severely compromised (LVEF \<40%) by imaging within 6 months prior to enrollment
  • Uncontrolled heart failure or (NYHA) Class III or IV
  • History of blood clotting, bleeding abnormalities or contraindication to anticoagulation (heparin, warfarin, or dabigatran)
  • History of a documented thromboembolic event (including ) within the past 12 months, or history of a documented left atrial appendage (LAA) thrombus
  • History of a documented symptomatic lacunar infarction within the past 12 months
  • Previous PCI/MI within the past 2 months
  • Coronary Artery Bypass Grafting (CABG) surgery within past 6 months
  • Valvular surgery, cardiac surgery (e.g., ventriculotomy, atriotomy) or valvular cardiac (surgical or percutaneous) procedure
  • Unstable angina pectoris within the past 6 months
  • Anticipated cardiac transplantation, cardiac surgery or other major surgery within the next 12 months
  • Significant pulmonary disease (e.g., restrictive pulmonary disease, constrictive or ) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms
  • Known significant PV anomaly that in the opinion of the investigator would preclude enrollment in this study
  • Has known pulmonary vein stenosis
  • Pre-existing hemi diaphragmatic paralysis
  • Acute illness, active systemic infection or sepsis
  • Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation
  • Severe mitral regurgitation (Regurgitant volume 60 mL/beat, Regurgitant fraction 50%, and/or Effective regurgitant orifice area 0.40cm\^2)
  • Presence of implanted pacemaker, Implantable Cardioverter-Defibrillator (ICD), recently implanted (within 6 months) LAAO device or other implanted metal cardiac device within the cardiac space that may interfere with the energy field created during the ablation procedure.
  • Presence of a condition that precludes vascular access (such as IVC filter)
  • Significant congenital anomaly or a medical problem that in the opinion of the investigator would preclude enrollment in this study
  • Categorized as vulnerable population and requires special treatment with respect to safeguards of well-being
  • Current enrollment in an study evaluating another device or drug
  • Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of childbearing age and plan on becoming pregnant during the course of the clinical investigation
  • less than 12 months
  • History of massive hemorrhage within the past 6 months
  • Presenting contra-indications for the devices
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    Pulsed Field (PF)/Radiofrequency (RF) Ablation System

    Participants with drug refractory symptomatic PAF who are candidates for atrial fibrillation ablation uses PF and RF energy to produce targeted intracardiac lesions for the treatment of atrial fibrillation.

    Device: Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation

Interventions

  • DevicePulsed Field (PF) /Radiofrequency (RF) Catheter ablation

    THERMOCOOL STSF catheter will be used in conjunction with TRUPULSE Generator to give PF ablation or RF ablation.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Primary Adverse Events (PAEs)

    An adverse event (AE) was any untoward medical occurrence, unintended disease or injury or any untoward clinical signs, including abnormal laboratory finding, in participants or users in context of clinical investigation, whether or not related to device/procedure. PAEs included the following adverse events: Device or procedure related death within 30 days of ablation procedure, esophageal perforating complications (atrio-esophageal fistula \[up to 90 days post ablation procedure\], esophago-pericardial fistula), myocardial infarction, cardiac tamponade/perforation up to 30 days post ablation, thromboembolism, stroke/cerebrovascular accident (CVA), transient ischemic attack (TIA), phrenic nerve paralysis, pulmonary vein stenosis (occurring anytime during 12 month follow-up period considered a PAE), major vascular access complication/bleeding, pericarditis, heart block, pulmonary edema (respiratory insufficiency), and vagal nerve injury/gastroparesis.

    Time frame: Up to 12 Months post ablation procedure on Day 0

  2. Percentage of Participants With Freedom From Documented (Symptomatic and Asymptomatic) Atrial Arrhythmia (Atrial Fibrillation [AF], Atrial Tachycardia [AT] or Atrial Flutter [AFL]) Episodes Based on Electrocardiographic Data and From All Failure Modes

    Percentage of participants with freedom from documented (symptomatic and asymptomatic) atrial arrhythmia (AF, AT or AFL) episodes based on electrocardiographic data and from all failure modes were reported. Atrial tachyarrhythmia (AF/AT/AFL of unknown origin) episodes were based on electrocardiographic data \[12-lead electrocardiogram(ECG) or greater than or equal to(\>=) 30 seconds on ECG or sponsor provided transtelephonic monitor (TTM) or Holter device\] during effectiveness evaluation period (Day 91 to Day 365) and any of following failure modes: acute procedural, repeat ablation, non-study device, anti-arrhythmic drug (AAD), continuous AF/AT/AFL of unknown origin, and any direct current cardioversion procedure during evaluation period for documented atrial tachyarrhythmia (AF/AT/AFL of unknown origin). AFL of unknown origin was defined as all AFL except those cavotricuspid isthmus dependent AFL as confirmed by 12-Lead ECG and entrainment maneuvers in an electrophysiology (EP) study.

    Time frame: From Day 91 up to Day 365 post ablation procedure on Day 0

Secondary outcomes

  1. Change From Baseline in Atrial Fibrillation Effect on Quality of Life (AFEQT) Total Score at Month 12

    Change from baseline in AFEQT total score at Month 12 was reported. AFEQT questionnaire was used to assess the quality-of-life post ablation procedure. The AFEQT questionnaire included 20 questions on a 7-point Likert scale. Questions 1-18 evaluated health-related quality of life (HRQoL), including AF-related symptoms (Questions 1-4), daily activities (Questions 5-12), and treatment concerns (Questions 13-18), while Questions 19-20 assessed participant satisfaction with treatment. The first 18 questions were used to calculate the overall AFEQT scores. Scores are transformed to a scale ranging from 0 to 100, where a score of 0 indicated complete disability and a score of 100 indicated no disability. Higher scores indicated improvement. The formula to calculate these scores is as follows: 100 minus(\[sum of severity for all questions answered minus number of questions answered\]\*100 divided by total number questions answered\*6).

    Time frame: Baseline, Month 12

07

Results

Posted Nov 17, 2026

Participant flow

Participant flow — Overall Study
MilestonePulsed Field (PF)/Radiofrequency (RF) Catheter Ablation
Started136
All treated (at) analysis set133
Completed127
Not completed9
Withdrew: Enrolled but not treated3
Withdrew: Death1
Withdrew: Lost to follow-up3
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryNumber of Participants With Primary Adverse Events (PAEs)

An adverse event (AE) was any untoward medical occurrence, unintended disease or injury or any untoward clinical signs, including abnormal laboratory finding, in participants or users in context of clinical investigation, whether or not related to device/procedure. PAEs included the following adverse events: Device or procedure related death within 30 days of ablation procedure, esophageal perforating complications (atrio-esophageal fistula \[up to 90 days post ablation procedure\], esophago-pericardial fistula), myocardial infarction, cardiac tamponade/perforation up to 30 days post ablation, thromboembolism, stroke/cerebrovascular accident (CVA), transient ischemic attack (TIA), phrenic nerve paralysis, pulmonary vein stenosis (occurring anytime during 12 month follow-up period considered a PAE), major vascular access complication/bleeding, pericarditis, heart block, pulmonary edema (respiratory insufficiency), and vagal nerve injury/gastroparesis.

Time frame:
Up to 12 Months post ablation procedure on Day 0
Reported as:
Count of participants · Participants
Number of Participants With Primary Adverse Events (PAEs)
ParticipantsPulsed Field (PF)/Radiofrequency (RF) Catheter Ablation
Number of Participants With Primary Adverse Events (PAEs)6
PrimaryPercentage of Participants With Freedom From Documented (Symptomatic and Asymptomatic) Atrial Arrhythmia (Atrial Fibrillation [AF], Atrial Tachycardia [AT] or Atrial Flutter [AFL]) Episodes Based on Electrocardiographic Data and From All Failure Modes

Percentage of participants with freedom from documented (symptomatic and asymptomatic) atrial arrhythmia (AF, AT or AFL) episodes based on electrocardiographic data and from all failure modes were reported. Atrial tachyarrhythmia (AF/AT/AFL of unknown origin) episodes were based on electrocardiographic data \[12-lead electrocardiogram(ECG) or greater than or equal to(\>=) 30 seconds on ECG or sponsor provided transtelephonic monitor (TTM) or Holter device\] during effectiveness evaluation period (Day 91 to Day 365) and any of following failure modes: acute procedural, repeat ablation, non-study device, anti-arrhythmic drug (AAD), continuous AF/AT/AFL of unknown origin, and any direct current cardioversion procedure during evaluation period for documented atrial tachyarrhythmia (AF/AT/AFL of unknown origin). AFL of unknown origin was defined as all AFL except those cavotricuspid isthmus dependent AFL as confirmed by 12-Lead ECG and entrainment maneuvers in an electrophysiology (EP) study.

Time frame:
From Day 91 up to Day 365 post ablation procedure on Day 0
Reported as:
Number · Percentage of participants
Percentage of Participants With Freedom From Documented (Symptomatic and Asymptomatic) Atrial Arrhythmia (Atrial Fibrillation [AF], Atrial Tachycardia [AT] or Atrial Flutter [AFL]) Episodes Based on Electrocardiographic Data and From All Failure Modes
Percentage of participantsPulsed Field (PF)/Radiofrequency (RF) Catheter Ablation
Percentage of Participants With Freedom From Documented (Symptomatic and Asymptomatic) Atrial Arrhythmia (Atrial Fibrillation [AF], Atrial Tachycardia [AT] or Atrial Flutter [AFL]) Episodes Based on Electrocardiographic Data and From All Failure Modes59.6 (50.5 to 68.6)
SecondaryChange From Baseline in Atrial Fibrillation Effect on Quality of Life (AFEQT) Total Score at Month 12

Change from baseline in AFEQT total score at Month 12 was reported. AFEQT questionnaire was used to assess the quality-of-life post ablation procedure. The AFEQT questionnaire included 20 questions on a 7-point Likert scale. Questions 1-18 evaluated health-related quality of life (HRQoL), including AF-related symptoms (Questions 1-4), daily activities (Questions 5-12), and treatment concerns (Questions 13-18), while Questions 19-20 assessed participant satisfaction with treatment. The first 18 questions were used to calculate the overall AFEQT scores. Scores are transformed to a scale ranging from 0 to 100, where a score of 0 indicated complete disability and a score of 100 indicated no disability. Higher scores indicated improvement. The formula to calculate these scores is as follows: 100 minus(\[sum of severity for all questions answered minus number of questions answered\]\*100 divided by total number questions answered\*6).

Time frame:
Baseline, Month 12
Reported as:
Mean · Score on scale
Change From Baseline in Atrial Fibrillation Effect on Quality of Life (AFEQT) Total Score at Month 12
Score on scalePulsed Field (PF)/Radiofrequency (RF) Catheter Ablation
Change From Baseline in Atrial Fibrillation Effect on Quality of Life (AFEQT) Total Score at Month 1231.59 ± 22.216

Adverse events

Collected over All cause mortality: From screening (90 days prior to Day 0) up to the end of the study (12 months); Serious and other adverse events: From Day 0 (post-procedure) up to the end of the study (12 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pulsed Field (PF)/Radiofrequency (RF) Catheter Ablation1/136 (0.7%)17/133 (12.8%)57/133 (42.9%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPulsed Field (PF)/Radiofrequency (RF) Catheter Ablation
BradycardiaCardiac disorders3/133
PericarditisCardiac disorders3/133
Atrial flutterCardiac disorders2/133
Pericardial effusionCardiac disorders2/133
PresyncopeNervous system disorders2/133
HypotensionVascular disorders2/133
Non-cardiac chest painGeneral disorders2/133
Atrioventricular blockCardiac disorders1/133
Atrioventricular block second degreeCardiac disorders1/133
Myocardial infarctionCardiac disorders1/133
Most frequent other events
Showing 10 of 61
Most frequent other events
EventPulsed Field (PF)/Radiofrequency (RF) Catheter Ablation
EcchymosisSkin and subcutaneous tissue disorders9/133
Atrial flutterCardiac disorders8/133
PericarditisCardiac disorders4/133
DiarrhoeaGastrointestinal disorders4/133
NauseaGastrointestinal disorders4/133
Atrial tachycardiaCardiac disorders3/133
Non-cardiac chest painGeneral disorders3/133
DizzinessNervous system disorders3/133
Obstructive sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders3/133
Chest painGeneral disorders2/133

Baseline characteristics

Safety analysis set included all enrolled participants who had insertion of the study catheter, regardless of energy delivery.

Age, Continuous
Age, Continuous(Years)Pulsed Field (PF)/Radiofrequency (RF) Catheter Ablation
Mean63.3 ± 9.89
Sex: Female, Male
Sex: Female, Male(Participants)Pulsed Field (PF)/Radiofrequency (RF) Catheter Ablation
Female57
Male76
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pulsed Field (PF)/Radiofrequency (RF) Catheter Ablation
Hispanic or Latino2
Not Hispanic or Latino116
Unknown or Not Reported15
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pulsed Field (PF)/Radiofrequency (RF) Catheter Ablation
American Indian or Alaska Native0
Asian8
Native Hawaiian or Other Pacific Islander0
Black or African American1
White116
More than one race0
Unknown or Not Reported8
08

Study locations

7 sites
  • Royal Prince Alfred Hospital
    Camperdown, 2050, Australia
  • Canberra Heart Rhythm
    Garran, 2605, Australia
  • Westmead Hospital
    Westmead, 2145, Australia
  • Southlake Regional Health Centre
    Newmarket, Ontario L3Y 2P9, Canada
  • University of Ottawa Heart Institute
    Ottawa, Ontario K1Y 4W7, Canada
  • Montreal Heart Institute
    Montreal, Quebec H1T 1C8, Canada
  • McGill University Health Centre
    Montreal, Quebec H3G 1A4, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Oct 2025, 20 months.

Results were first posted in Nov 2026, 1 year after primary completion.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 20 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2024
First posted
Feb 22, 2024
StartActual
Feb 28, 2024
Primary completionActual
Oct 28, 2025
CompletionActual
Oct 28, 2025
Results first posted
Nov 17, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 17, 2026
Enrollment
135→136
Oct 16, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedNumber of Participants withWith Primary Adverse Events (PAEs)Time frame: Within one week (7 days) post-procedure → Up to 12 Months post ablation procedure on Day 0
  • EditedRatePercentage of Participants With Freedom fromFrom Documented (Symptomatic and Asymptomatic) Atrial Arrhythmia (Atrial Fibrillation ([AF)], Atrial Tachycardia ([AT)] or Atrial Flutter ([AFL]) of Unknown Origin) within 91-365 Days Post Index ProcedureEpisodes Based on Electrocardiographic Data and From All Failure ModesTime frame: Within Day 91 to Day 365 post-procedure → From Day 91 up to Day 365 post ablation procedure on Day 0
Nov 17, 2026
Documents
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedChange fromFrom Baseline in Atrial Fibrillation Effect on Quality of Life (AFEQT) Total Score at Month 12Time frame: Baseline, Month 12
Nov 17, 2026
Show all 2 updates
  1. Nov 17, 2026
    Results posted
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedNumber of Participants withWith Primary Adverse Events (PAEs)Time frame: Within one week (7 days) post-procedure → Up to 12 Months post ablation procedure on Day 0
    • EditedRatePercentage of Participants With Freedom fromFrom Documented (Symptomatic and Asymptomatic) Atrial Arrhythmia (Atrial Fibrillation ([AF)], Atrial Tachycardia ([AT)] or Atrial Flutter ([AFL]) of Unknown Origin) within 91-365 Days Post Index ProcedureEpisodes Based on Electrocardiographic Data and From All Failure ModesTime frame: Within Day 91 to Day 365 post-procedure → From Day 91 up to Day 365 post ablation procedure on Day 0
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedChange fromFrom Baseline in Atrial Fibrillation Effect on Quality of Life (AFEQT) Total Score at Month 12Time frame: Baseline, Month 12
  2. Oct 16, 2026
    Enrollment 135→136
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06272981
Responsible party
Sponsor
First posted
Feb 22, 2024
Start date
Feb 28, 2024
Primary completion
Oct 28, 2025
Completion
Oct 28, 2025
Results posted
Nov 17, 2026
Last update
Nov 17, 2026

Study contacts

Biosense Webster, Inc. Clinical Trial
study director · Biosense Webster, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion